tert-Butyl 4-(2-(3-bromophenoxy)ethyl)piperazine-1-carboxylate

Catalog No. :
ACTBNS742
CAS No. :
1227954-64-4
Molecular Formula :
C17H25BrN2O3
Molecular Weight :
385.30

IUPAC Name:tert-butyl 4-(2-(3-bromophenoxy)ethyl)piperazine-1-carboxylate

tert-Butyl 4-(2-(3-bromophenoxy)ethyl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$112.00Login to see priceInquiryInquiry
1g97%$281.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(2-(3-bromophenoxy)ethyl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-(2-(3-bromophenoxy)ethyl)piperazine-1-carboxylate
MDL No.MFCD11973601
Molecular FormulaC17H25BrN2O3
Molecular Weight385.30
SMILESO=C(N1CCN(CCOC2=CC=CC(Br)=C2)CC1)OC(C)(C)C
InChI KeyHQGHEGRFJLUEFR-UHFFFAOYSA-N
Synonymtert-Butyl 4-[2-(3-bromophenoxy)-ethyl]piperazine-1-carboxylate;1-Piperazinecarboxylic acid, 4-[2-(3-bromophenoxy)ethyl]-, 1,1-dimethylethyl ester
CAS No.1227954-64-4

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACTBNS742 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTBNS742 route product structure diagram
    ACTBNS7421227954-64-4
Inquiry

2. ACTBNS742 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  4. Then
  5. ACTBNS742 route product structure diagram
    ACTBNS7421227954-64-4
Inquiry

Comments (0)